Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037069 | 1.00 | RAB9A (0.48) | RAB9AMAPTSMN1; SMN2CASP3HPGD | |
| SCHEMBL30035606 | 1.00 | RAB9A (0.48) | RAB9AMAPTSMN1; SMN2CASP3HPGD | |
| SCHEMBL30036068 | 1.00 | RAB9A (0.48) | RAB9AMAPTSMN1; SMN2CASP3HPGD | |
| SCHEMBL30035872 | 1.00 | RAB9A (0.48) | RAB9AMAPTSMN1; SMN2CASP3HPGD | |
| SCHEMBL30037084 | 1.00 | RAB9A (0.48) | RAB9AMAPTSMN1; SMN2CASP3HPGD | |
| SCHEMBL30036373 | 1.00 | RAB9A (0.48) | RAB9AMAPTSMN1; SMN2CASP3HPGD | |
| SCHEMBL16154841 | 0.91 | PPARA (0.42) | RAB9AMAPTSMN1; SMN2CASP3HPGD | |
| SCHEMBL17685738 | 0.91 | PPARA (0.42) | RAB9AMAPTSMN1; SMN2CASP3HPGD | |
| SCHEMBL15923064 | 0.90 | KMT2A (0.52) | RAB9AMAPTSMN1; SMN2HPGDKMT2A | |
| SCHEMBL15923238 | 0.90 | KMT2A (0.52) | RAB9AMAPTSMN1; SMN2HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233964-A | Single component delivery system for nucleic acids | 宾夕法尼亚大学理事会 | 2024-12-31 | — | — | CN | disclosed |
| US-20240252677-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252677-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | TLR3, TLR9, ADAR | RAB9A 4225/4885MAPT 3202/4885SMN1; SMN2 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.